These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 11791391

  • 1. [Tumor markers in lung cancer].
    Niho S, Shinkai T.
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
    [Abstract] [Full Text] [Related]

  • 2. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N.
    Anticancer Res; 2003 Dec; 23(2A):885-93. PubMed ID: 12820318
    [Abstract] [Full Text] [Related]

  • 3. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, Yamaguchi K.
    Anticancer Res; 1999 Dec; 19(4A):2673-8. PubMed ID: 10470218
    [Abstract] [Full Text] [Related]

  • 4. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM, Sauer-Eppel H, Bruzdziak TH.
    Anticancer Res; 2007 Dec; 27(4A):1911-5. PubMed ID: 17649794
    [Abstract] [Full Text] [Related]

  • 5. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R, Auge JM, Filella X, Viñolas N, Alicarte J, Domingo JM, Ballesta AM.
    Anticancer Res; 2005 Dec; 25(3A):1773-8. PubMed ID: 16033098
    [Abstract] [Full Text] [Related]

  • 6. [Lung cancer].
    Komagata H, Yoneda S.
    Gan To Kagaku Ryoho; 2004 Oct; 31(10):1609-13. PubMed ID: 15508459
    [Abstract] [Full Text] [Related]

  • 7. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
    Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D, Stieber P.
    Clin Cancer Res; 2008 Dec 01; 14(23):7813-21. PubMed ID: 19047109
    [Abstract] [Full Text] [Related]

  • 8. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T, Bombardieri E.
    Eur J Clin Chem Clin Biochem; 1994 Mar 01; 32(3):189-99. PubMed ID: 7518259
    [Abstract] [Full Text] [Related]

  • 9. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M, Tohda Y, Iwanaga T, Uejima H, Nagasaka Y, Nakajima S.
    Cancer; 1996 Apr 01; 77(7):1274-7. PubMed ID: 8608502
    [Abstract] [Full Text] [Related]

  • 10. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S, Bombardieri E.
    Anticancer Res; 1999 Apr 01; 19(4C):3613-8. PubMed ID: 10629660
    [Abstract] [Full Text] [Related]

  • 11. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
    Wójcik E, Kulpa JK, Sas-Korczyńska B, Korzeniowski S, Jakubowicz J.
    Anticancer Res; 2008 Apr 01; 28(5B):3027-33. PubMed ID: 19031951
    [Abstract] [Full Text] [Related]

  • 12. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F, Aydiner A, Topuz E, Yasasever V, Karadeniz A, Saip P.
    J Exp Clin Cancer Res; 2000 Dec 01; 19(4):477-81. PubMed ID: 11277326
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C, Mohn-Staudner A, Vetter H, Kokron O, Baumgartner G, Scheiner W, Zwick H, Koderhold G, Alth G, Dudczak R.
    Wien Klin Wochenschr; 1996 Dec 01; 108(15):467-72. PubMed ID: 8806188
    [Abstract] [Full Text] [Related]

  • 14. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T.
    Anticancer Res; 2001 Dec 01; 21(4B):3085-92. PubMed ID: 11712815
    [Abstract] [Full Text] [Related]

  • 15. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
    Schneider J, Philipp M, Salewski L, Velcovsky HG.
    Clin Lab; 2003 Dec 01; 49(1-2):35-42. PubMed ID: 12593474
    [Abstract] [Full Text] [Related]

  • 16. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Dec 01; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 17. [The value of serum tumor marker in the diagnosis of lung cancer].
    Shi GL, Hu XL, Yue SD, Song CX.
    Zhonghua Zhong Liu Za Zhi; 2005 May 01; 27(5):299-301. PubMed ID: 15996327
    [Abstract] [Full Text] [Related]

  • 18. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
    Song WA, Liu X, Tian XD, Wang W, Liang CY, Zhang T, Guo JT, Peng YH, Zhou NK.
    Chin Med J (Engl); 2011 Oct 01; 124(20):3244-8. PubMed ID: 22088515
    [Abstract] [Full Text] [Related]

  • 19. Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma.
    Kohno N, Hirasawa Y, Kondo K, Fujioka S, Fujino S, Abe M, Yokoyama A, Hiwada K, Watanabe K, Nishimura J.
    Cancer Detect Prev; 1997 Oct 01; 21(2):124-8. PubMed ID: 9101072
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.
    Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E.
    Anticancer Res; 2000 Oct 01; 20(6D):5053-8. PubMed ID: 11326667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.